Drug Profile

EG 402

Alternative Names: EG-402

Latest Information Update: 15 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Retinopathy of prematurity
New Molecular Entity Yes
Available For Licensing Yes

10 Oct 2024 Preclinical trials in Retinopathy of prematurity in USA(Ophthalmic) prior to October 2024 (Evergreen Therapeutics pipeline, October 2024)
16 Feb 2023 Evergreen Therapeutics has patent protection for EG 402 before February 2023 (Evergreen Therapeutics pipeline, February 2023)
16 Feb 2023 EG 402 receives Orphan Drug status for Retinopathy of prematurity in USA before February 2023 (Evergreen pipeline, February 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com